Weighing the Impact of Obesity

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype. 

The research has been pretty clear: Obese women with breast cancer are at higher risk for recurrence and death. But now, new findings suggest the poor outcome for obese patients depends on whether they have the most common subtype—estrogen receptor–positive, HER2-negative breast cancer. 

Obese women treated with chemotherapy after surgery had worse overall survival and disease-free survival than non-obese patients—but only if they had estrogen receptor–positive, or hormone-sensitive, cancers. The findings, presented Thursday at the San Antonio Breast Cancer Symposium, are the first to show that obesity’s harmful effects may be confined to this group of patients. Women with other types of breast cancer, however, shouldn’t consider themselves safe just yet, experts caution.

Obese Americans make up a third of the adult population. A person is considered obese if their body mass index—a calculation of body fat that uses weight in relation to height—is 30 or higher. So a 5-foot-5-inch woman would be considered obese at 180 pounds.

Using information from a previous clinical trial, investigators examined the relationship between body mass index and survival in early-stage patients. When researchers teased out the data by breast cancer subtype, they uncovered a trend toward worse survival only among obese women with hormone-sensitive tumors.

Hoping to confirm this finding, the researchers analyzed data from two other studies—one that included patients with estrogen receptor–positive cancers, and a second that comprised estrogen receptor–positive cancers. HER2 status was unknown in these two studies, but, like the first trial, patients had received chemotherapy after surgical removal of the tumor.

Based on combined data from the three studies, obese patients who do not have hormone-sensitive breast cancer appear to be spared the harmful effects of obesity, said lead investigator Joseph Sparano, MD, professor of medicine and women’s health at Albert Einstein College of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in Bronx, New York. The findings, however, would need to be confirmed in other studies that look at all breast cancer subtypes, Sparano noted. 

Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk. At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.

Women with estrogen receptor–positive breast cancer should not feel protected, said Pamela Goodwin, MD, a clinician-scientist at Mount Sinai Hospital in Toronto and an associate professor of medicine at the University of Toronto. “Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk,” said Goodwin, who was not involved in the study. “At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.”

The most likely explanation for the findings may be that high insulin levels—a byproduct of obesity—are driving the growth of breast tumors, said Goodwin.

Related Articles
Extracting Clues from a Rare Type of Breast Cancer
A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype called metaplastic breast cancer, was one of the top studies presented at the Miami Breast Cancer Conference this year.
Chemobrain—It’s Real, It’s Complex, and the Science Is Still Evolving
Talk with almost any cancer survivor, and he or she is likely to bring up the topic of “chemobrain,” that fuzzy, murky state that patients blame for impaired memory. A review of the research shows how we're focusing on the problem.
“Cross-Pollination” of Breast Cancer Knowledge was Encouraged at SABCS
While science sometimes moves forward in quantum leaps, it more often advances in small steps, and this year’s San Antonio Breast Cancer Symposium demonstrated both sides of that coin.
Dating, Love, Sex ... and Cancer
I went into dating after cancer with one goal, a decent date, and I got far more than I ever dreamed.
Is Radiation Therapy in Early-Stage Breast Cancer Always Necessary?
Women diagnosed with early-stage breast cancer have a variety of decisions to make regarding treatment, but it's important for patients to realize all of their options when making those medical decisions.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familiar cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
  • photo